SGK İlaç DavasıAkıllı Kanser İlaçlarıEndikasyon Dışı İlaç
Legal Processes for SGK Coverage of Trastuzumab Deruxtecan (Enhertu)
This article examines the administrative and judicial avenues available when the Social Security Institution (SGK) declines to cover the biologic drug Enhertu (trastuzumab deruxtecan). It provides an evaluation of interim injunctions, case law on off-label drug reimbursement, and the current regulatory framework.
By: Av. Barış Ürün12 min read